Cooperation between cAMP signalling and sulfonylurea in insulin secretion

Diabetes, Obesity and Metabolism

Volumn 16, Issue , 2014, Pages 118-125

  Shibasaki, T ^a   Takahashi, T ^a   Takahashi, H ^a   Seino, S ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

cAMP; Epac2A; Insulin secretion; PKA; Sulfonylurea

Indexed keywords

ADRENALIN; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GUANINE NUCLEOTIDE BINDING PROTEIN; INCRETIN; INSULIN; PLECKSTRIN; RAP1 PROTEIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GUANINE NUCLEOTIDE EXCHANGE FACTOR; RAP1A PROTEIN, HUMAN; RAPGEF4 PROTEIN, HUMAN;

AMINO TERMINAL SEQUENCE; BINDING AFFINITY; CELLULAR DISTRIBUTION; CONFORMATIONAL TRANSITION; DIABETES MELLITUS; DIABETIC PATIENT; ENZYME PHOSPHORYLATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; HYDROGEN BOND; HYPERGLYCEMIA; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN RESISTANCE; MOLECULAR DOCKING; MUTATIONAL ANALYSIS; NONHUMAN; PANCREAS ISLET BETA CELL; REVIEW; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; AGONISTS; ANIMAL; BIOLOGICAL MODEL; BLOOD; CHEMISTRY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; ENZYMOLOGY; GLUCOSE BLOOD LEVEL; METABOLISM; PHYSIOLOGY; SECOND MESSENGER; SECRETION (PROCESS);

ANIMALS; BLOOD GLUCOSE; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DIABETES MELLITUS, TYPE 2; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; MODELS, BIOLOGICAL; RAP1 GTP-BINDING PROTEINS; SECOND MESSENGER SYSTEMS; SULFONYLUREA COMPOUNDS;

EID: 84908507287     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12343     Document Type: Review

References (64)

1. Beavo JA, Brunton LL. Cyclic nucleotide research - still expanding after half a century. Nat Rev Mol Cell Biol 2002; 3: 710-718.
2. Evans GJ, Morgan A. Regulation of the exocytotic machinery by cAMP-dependent protein kinase: implications for presynaptic plasticity. Biochem Soc Trans 2003; 31: 824-827.
3. Seino S, Shibasaki T. PKA-dependent and PKA-independent pathways for cAMP-regulated exocytosis. Physiol Rev 2005; 85: 1303-1342.
4. Song WJ, Seshadri M, Ashraf U et al. Snapin mediates incretin action and augments glucose-dependent insulin secretion. Cell Metab 2011; 13: 308-319.
5. Brozzi F, Lajus S, Diraison F et al. MyRIP interaction with MyoVa on secretory granules is controlled by the cAMP-PKA pathway. Mol Biol Cell 2012; 23: 4444-4455.
6. Holz GG, Kang G, Harbeck M, Roe MW, Chepurny OG. Cell physiology of cAMP sensor Epac. J Physiol 2006; 577: 5-15.
7. Kawasaki H, Springett GM, Mochizuki N et al. A family of cAMP-binding proteins that directly activate Rap1. Science 1998; 282: 2275-2279.
8. Ozaki N, Shibasaki T, Kashima Y et al. cAMP-GEFII is a direct target of cAMP in regulated exocytosis. Nat Cell Biol 2000; 2: 805-811.
9. de Rooij J, Rehmann H, van Triest M, Cool RH, Wittinghofer A, Bos JL. Mechanism of regulation of the Epac family of cAMP-dependent RapGEFs. J Biol Chem 2000; 275: 20829-20836.
10. Drucker DJ. The biology of incretin hormones. Cell Metab 2006; 3: 153-165.
11. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007; 87: 1409-1439.
12. Nauck MA. Unraveling the science of incretin biology. Am J Med 2009; 122(Suppl): S3-S10.
13. Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: similarities and differences. J Diabetes Invest 2010; 1: 8-23.
14. Thorens B. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci U S A 1992; 89: 8641-8645.
15. Usdin TB, Mezey E, Button DC, Brownstein MJ, Bonner TI. Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology 1993; 133: 2861-2870.
16. Yamada Y, Hayami T, Nakamura K et al. Human gastric inhibitory polypeptide receptor: cloning of the gene (GIPR) and cDNA. Genomics 1995; 29: 773-776.
17. Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009; 5: 262-269.
18. Nauck MA. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med 2011; 124(Suppl): S3-S18.
19. Yabe D, Seino Y. Two incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and β cell preservation. Prog Biophys Mol Biol 2011; 107: 248-256.
20. Seino S. ATP-sensitive potassium channels: a model of heteromultimeric potassium channel/receptor assemblies. Annu Rev Physiol 1999; 61: 337-362.
21. Zhang CL, Katoh M, Shibasaki T et al. The cAMP sensor Epac2 is a direct target of antidiabetic sulfonylurea drugs. Science 2009; 325: 607-610.
22. Seino S, Zhang CL, Shibasaki T. Sulfonylurea action re-revisited. J Diabetes Invest 2010; 1: 37-39.
23. Ahren B. Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nat Rev Drug Discov 2009; 8: 369-385.
24. Amisten S, Salehi A, Rorsman P, Jones PM, Persaud SJ. An atlas and functional analysis of G-protein coupled receptors in human islets of Langerhans. Pharmacol Ther 2013; 139: 359-391.
25. Ahren B. Autonomic regulation of islet hormone secretion--implications for health and disease. Diabetologia 2000; 43: 393-410.
26. 2+, cAMP, and phospholipid-derived messengers in coupling mechanisms of insulin secretion. Physiol Rev 1987; 67: 1185-1248.
27. Sharp GW. Mechanisms of inhibition of insulin release. Am J Physiol 1996; 271: 1781-1799.
28. Broglio F, Arvat E, Benso A et al. Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J Clin Endocrinol Metab 2001; 86: 5083-5086.
29. Miller RE. Pancreatic neuroendocrinology: peripheral neural mechanisms in the regulation of the Islets of Langerhans. Endocr Rev 1981; 2: 471-494.
30. Morgan NG. Regulation of insulin secretion by α2-adrenergic agonists. Trends Pharmacol Sci 1987; 8: 369-370.
31. Iversen J. Adrenergic receptors and the secretion of glucagon and insulin from the isolated, perfused canine pancreas. J Clin Invest 1973; 52: 2102-2116.
32. Itoh M, Gerich JE. Adrenergic modulation of pancreatic somatostatin, insulin, and glucagon secretion: evidence for differential sensitivity of islet A, B, and D cells. Metabolism 1982; 31: 715-720.
33. 2+ and insulin release. Mol Pharmacol 1985; 28: 100-106.
34. Halter JB, Beard JC, Porte D Jr. Islet function and stress hyperglycemia: plasma glucose and epinephrine interaction. Am J Physiol 1984; 247: 47-52.
35. Krebs EG, Beavo JA. Phosphorylation-dephosphorylation of enzymes. Annu Rev Biochem 1979; 48: 923-959.
36. Tasken K, Skalhegg BS, Tasken KA et al. Structure, function, and regulation of human cAMP-dependent protein kinases. Adv Second Messenger Phosphoprotein Res 1997; 31: 191-204.
37. Beene DL, Scott JD. A-kinase anchoring proteins take shape. Curr Opin Cell Biol 2007; 19: 192-198.
38. Fraser ID, Tavalin SJ, Lester LB et al. A novel lipid-anchored A-kinase anchoring protein facilitates cAMP-responsive membrane events. Embo J 1998; 17: 2261-2272.
39. Lester LB, Langeberg LK, Scott JD. Anchoring of protein kinase A facilitates hormone-mediated insulin secretion. Proc Natl Acad Sci U S A 1997; 94: 14942-14947.
40. Kaihara KA, Dickson LM, Jacobson DA et al. β-Cell-specific protein kinase A activation enhances the efficiency of glucose control by increasing acute-phase insulin secretion. Diabetes 2013; 62: 1527-1536.
41. Goehring AS, Pedroja BS, Hinke SA, Langeberg LK, Scott JD. MyRIP anchors protein kinase A to the exocyst complex. J Biol Chem 2007; 282: 33155-33167.
42. Bos JL. Epac proteins: multi-purpose cAMP targets. Trends Biochem Sci 2006; 31: 680-686.
43. de Rooij J, Zwartkruis FJ, Verheijen MH et al. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature 1998; 396: 474-477.
44. Niimura M, Miki T, Shibasaki T, Fujimoto W, Iwanaga T, Seino S. Critical role of the N-terminal cyclic AMP-binding domain of Epac2 in its subcellular localization and function. J Cell Physiol 2009; 219: 652-658.
45. Ueno H, Shibasaki T, Iwanaga T et al. Characterization of the gene EPAC2: structure, chromosomal localization, tissue expression, and identification of the liver-specific isoform. Genomics 2001; 78: 91-98.
46. Shibasaki T, Takahashi H, Miki T et al. Essential role of Epac2/Rap1 signaling in regulation of insulin granule dynamics by cAMP. Proc Natl Acad Sci U S A 2007; 104: 19333-19338.
47. Seino S. Cell signalling in insulin secretion: the molecular targets of ATP, cAMP and sulfonylurea. Diabetologia 2012; 55: 2096-2108.
48. Seino S, Takahashi H, Fujimoto W, Shibasaki T. Roles of cAMP signalling in insulin granule exocytosis. Diabetes Obes Metab 2009; 11(Suppl 4): 180-188.
49. Seino S, Shibasaki T, Minami K. Dynamics of insulin secretion and the clinical implications for obesity and diabetes. J Clin Invest 2011; 121: 2118-2125.
50. Kashima Y, Miki T, Shibasaki T et al. Critical role of cAMP-GEFII-Rim2 complex in incretin-potentiated insulin secretion. J Biol Chem 2001; 276: 46046-46053.
51. Yasuda T, Shibasaki T, Minami K et al. Rim2alpha determines docking and priming states in insulin granule exocytosis. Cell Metab 2010; 12: 117-129.
52. Leech CA, Dzhura I, Chepurny OG et al. Molecular physiology of glucagon-like peptide-1 insulin secretagogue action in pancreatic β cells. Prog Biophys Mol Biol 2011; 107: 236-247.
53. 2+ by glucagon-like peptide-1 receptor agonist exendin-4 is disrupted in β-cells of phospholipase C-epsilon knockout mice. J Physiol 2010; 588: 4871-4889.
54. Kai AK, Lam AK, Chen Y et al. Exchange protein activated by cAMP 1 (Epac1)-deficient mice develop β-cell dysfunction and metabolic syndrome. Faseb J 2013; 27: 4122-4135.
55. ATP channels and islet hormone secretion: new insights and controversies. Nat Rev Endocrinol 2013; 9: 660-669.
56. ATP channel-deficient mice. Proc Natl Acad Sci U S A 1998; 95: 10402-10406.
57. ATP channel-independent regulation of insulin secretion. J Biol Chem 2000; 275: 9270-9277.
58. Shiota C, Larsson O, Shelton KD et al. Sulfonylurea receptor type 1 knock-out mice have intact feeding-stimulated insulin secretion despite marked impairment in their response to glucose. J Biol Chem 2002; 277: 37176-37183.
59. Takahashi T, Shibasaki T, Takahashi H et al. Antidiabetic sulfonylureas and cAMP cooperatively activate Epac2A. Sci Signal 2013; 6: ra94.
60. Herbst KJ, Coltharp C, Amzel LM, Zhang J. Direct activation of Epac by sulfonylurea is isoform selective. Chem Biol 2011; 18: 243-251.
61. Naim M, Bhat S, Rankin KN et al. Solvated interaction energy (SIE) for scoring protein-ligand binding affinities. 1. Exploring the parameter space. J Chem Inf Model 2007; 47: 122-133.
62. Rehmann H, Das J, Knipscheer P, Wittinghofer A, Bos JL. Structure of the cyclic-AMP-responsive exchange factor Epac2 in its auto-inhibited state. Nature 2006; 439: 625-628.
63. Rehmann H, Arias-Palomo E, Hadders MA, Schwede F, Llorca O, Bos JL. Structure of Epac2 in complex with a cyclic AMP analogue and RAP1B. Nature 2008; 455: 124-127.
64. Yabe D, Seino Y. Dipeptidyl peptidase-4 inhibitors 4 inhibitors and sulfonylureas for type 2 diabetes: Friend or Foe? J Diabetes Invest. In press.